Nevada's caucus results have investors nervous about the hospital and urgent care provider's future.
Berkshire Hathaway's biggest buys last quarter may surprise you.
The specialized health services provider's fourth-quarter financials were uninspiring.
Consumer complaints against the teeth-aligner company have investors frowning.
Tazemetostat is already approved to treat advanced epithelioid sarcoma; the biotech is now pursing an approval for advanced follicular lymphoma.
The company's offer to buy back shares was overtendered, resulting in a prorated deal.
The company's latest financial results are sparking investor optimism.
Retainer rings on its MiniMed 630G and MiniMed 670G insulin pumps have been breaking, which can lead to a health hazard for users.
Cabozantinib may help delay the need for chemotherapy in advanced patients.
Investors are optimistic a turnaround will pay off in 2020.
Twist will pay Agilent $22.5 million and receive a license to aspects of its technology.
The company's secondary stock offering was priced below its prior-day closing price.
The company's frown line treatment moved closer to commercialization today.
Investors are increasingly optimistic conversational commerce will disrupt how consumers connect to businesses.
The marketing, sales, and service software company won widespread support from Wall Street analysts last month.
Optimism growth tied to Disney+'s global roll-out helped shares surge higher last month.
The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.
The pharmaceutical giant reported top- and bottom-line results that exceeded analysts' estimates.
The pharmacy giant is offering health insurers and employers a tool to eliminate out-of-pocket costs for diabetics that won't raise their costs either.
One of the largest pharmaceutical companies in the world will leverage its antiviral research program to attack the rapidly spreading illness.